View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 7, 2019

Orphan Technologies starts dosing in OT-58’s Phase I/II trial

Orphan Technologies has commenced dosing patients in a Phase I/II CBS-HCY-01 clinical trial of OT-58 for the treatment of classical homocystinuria, a rare metabolic disorder.

Orphan Technologies has commenced dosing patients in a Phase I/II CBS-HCY-01 clinical trial of OT-58 for the treatment of classical homocystinuria, a rare metabolic disorder.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The disease is characterised by elevated amino acid homocysteine levels that lead to debilitating effects such as severe cardiovascular, skeletal, neurologic and ophthalmologic complications.

OT-58 is a recombinant enzyme therapy developed to minimise plasma and tissue homocysteine levels.

The double-blind, randomised, placebo-controlled CBS-HCY-01 trial is designed to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects of subcutaneous OT-58.

Up to 20 patients suffering from cystathionine beta-synthase deficient homocystinuria will be enrolled in the trail.

The company is also conducting a natural history study to determine progression of disease in homocystinuria patients.

“We believe that OT-58 may be a dramatic advance for these patients and we look forward to the results of this new study.”

Orphan Technologies CEO Frank Glavin said: “We believe that OT-58 may be a dramatic advance for these patients and we look forward to the results of this new study.

“In parallel, we are conducting a comprehensive and prospective natural history study of patients with classical homocystinuria as part of our exhaustive approach to understanding and treating this underdiagnosed and underserved disease.”

Primary endpoint of the Phase I part of the CBS-HCY-01 trial is safety, measured as incidence of treatment-emergent adverse events.

The study will also evaluate pharmacokinetic and pharmacodynamic parameters as secondary outcome measures, including changes in total plasma homocysteine and cognitive function.

Participants will also receive eye assessments to check ocular health and dual-energy x-ray absorptiometry (DEXA) to measure bone mineral density. Patient-Reported Outcomes Measurement Information System (PROMIS) will be used to measure the wellbeing of the patient.

The Phase I/II trial was initiated in December last year and is expected to be completed in October.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena